- POSITIVE
Annual Revenue Evoq Remedies Mar-2026 Annual Revenue is Rs 27 Cr which is growth of 88.8% YoY.
- NEGATIVE
Annual Net Profit Evoq Remedies Mar-2026 Annual Net Profit is Rs -0 Cr which is growth of -372.0% YoY.
aboutEvoq Remedies Ltd. is a pharmaceutical company primarily engaged in the trading of pharmaceutical products and raw materials. Based in Ahmedabad, the company operates within the SME segment and focuses on the distribution and supply of pharmaceutical... Read More
1.61-0.08(-4.73%)
12,000
BSE Volume
BSE 16 Nov, 2026 12:04 PM (IST)
Check Before You Buy
VIEW FULL CHECKLISTLow rank
3Positive11Negative
21.4%Pass in checklist
Check P/E Buy Sell Zone
This stock has negative PE
Evoq Remedies Stock Price Analysis
Day Price Range-4.7% 1 Day return | 1.6 (LTP) 1.61.7 LowHigh |
|---|---|
Week Price Range3.2% 1 Week return | 1.6 (LTP) 1.61.7 LowHigh |
Month Price Range-10.6% 1 Month return | 1.6 (LTP) 1.52 LowHigh |
52 Week Price Range-61.1% 1 Year return | 1.6 (LTP) 1.44.3 LowHigh |
Competitors/Peers
Annual
Balance Sheet
Ratios
Cash Flow
Documents
Evoq Remedies annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|
0.5% | 21.8% | 26.8 | 14.2 | 6.3 | 26.4 | 16.8 | 10 | 9.1 | 3.3 | ||
Operating Exp. Ann. | 3.9% | 24.3% | 27 | 14 | 5.7 | 24.1 | 15.3 | 9.1 | 9.1 | 3.2 | |
Operating Profit Ann. | - | - | -1.5 | -2.2 | -1.6 | -3.7 | 1.5 | 1 | 0 | ||
OPM Ann. % | - | - | -5.42% | -15.79% | -25.96% | -14.13% | 8.72% | 9.52% | 0.01% | 0.50% | |
3.9% | 24.3% | 27 | 14 | 5.7 | 24.1 | 15.3 | 9.1 | 9.1 | 3.2 | ||
EBITDA Ann. | - | - | -0.2 | 0.2 | 0.6 | 2.3 | 1.5 | 1 | 0 | ||
EBITDA Ann. margin % | - | - | -0.75% | 1.25% | 9.81% | 8.67% | 8.72% | 9.52% | 0.01% | 0.50% | |
Interest Ann. | - | - | |||||||||
Depr. | - | - | 0.1 | 0.1 | 0 | ||||||
PBT Ann. | - | - | -0.3 | 0.1 | 0.6 | 2.3 | 1.5 | 1 | 0 | ||
Tax Ann. | - | - | -0 | 0 | 0.2 | 0.7 | 0.4 | 0.2 | |||
- | - | -0.2 | 0.1 | 0.5 | 1.6 | 1.1 | 0.7 | 0 | |||
Net Profit Ann. | - | - | -0.2 | 0.1 | 0.5 | 1.6 | 1.1 | 0.7 | 0 | ||
NPM Ann. % | - | - | -0.94% | 0.75% | 11.16% | 7.94% | 6.50% | 7.12% | 0.34% | ||
EPS Adj. latest Ann. | - | - | -0.1 | 0 | 0.2 | 0.7 | 0.4 | 0.3 |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
88.7%
2Y CAGR
106.3%
3Y CAGR
0.5%
5Y CAGR
21.8%
7Y CAGR
34.9%
Total Revenue Annual growth is higher than historical averages.
Operating Exp. Ann.
1Y CHG
92.9%
2Y CAGR
117.6%
3Y CAGR
3.9%
5Y CAGR
24.3%
7Y CAGR
35.6%
Operating Expenses Annual Cr growth is higher than historical averages.
Evoq Remedies Technical Analysis
Evoq Remedies EMA & SMA
Bearish-8
0 bullish, 8 bearish
Bullish0
Bearish8
| 5 Day | 1.6 |
|---|---|
| 10 Day | 1.6 |
| 12 Day | 1.6 |
| 20 Day | 1.6 |
| 26 Day | 1.7 |
|---|---|
| 50 Day | 1.7 |
| 100 Day | 1.9 |
| 200 Day | 2.5 |
Evoq Remedies Delivery And Volume
Daily Avg. Delivery Volume %
13 Nov, 2026100.0%
Week100.0%
Month100.0%
Evoq Remedies Active Candlesticks
Marubozu Uptrend Belt Hold Uptrend Closing Marubozu Uptrend Long Line Uptrend
Legend
Positive IndicatorNeutral IndicatorNegative Indicator
Evoq Remedies Resistance and Support
1.67
Pivot
| First Resistance | 1.7 |
|---|---|
| Second Resistance | 1.7 |
| Third Resistance | 1.8 |
| First Support | 1.7 |
|---|---|
| Second Support | 1.6 |
| Third Support | 1.6 |
| Day RSI | 53.5 |
|---|---|
| Day MACD | 0 |
| Day MFI | 43.3 |
| Day MACD Signal Line | 0 |
Evoq Remedies Beta
| 1 Month | -0.7 |
|---|---|
| 1 Year | -0.2 |
| 3 Month | -0.2 |
|---|---|
| 3 Year | -0.1 |
Evoq Remedies Price Change Analysis
↓-10.6%
Over 1 Month
LowHigh
1.52.0
↓-11.5%
Over 3 Months
LowHigh
1.42.0
↓-50.3%
Over 6 Months
LowHigh
1.43.7
↓-61.1%
Over 1 Year
LowHigh
1.44.3
Evoq Remedies Deals - Insider, Bulk, Block and SAST
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| SURYA PRAKASH JETHLIA | Bulk | Sell | 15 Jun 2026 | 2.64 | 164,000 | BSE |
| JANAKI BOOPALAN RAJESWARI | Bulk | Sell | 11 Dec 2025 | 2.62 | 128,000 | BSE |
| NIRAJ RAJNIKANT SHAH | Bulk | Sell | 08 Dec 2025 | 2.79 | 176,000 | BSE |
| NIRAJ RAJNIKANT SHAH | Bulk | Sell | 28 Nov 2025 | 3.05 | 144,000 | BSE |
| NIRAJ RAJNIKANT SHAH | Bulk | Sell | 26 Nov 2025 | 3.11 | 144,000 | BSE |
| PANCHAL | Bulk | Sell | 25 Nov 2025 | 3.23 | 184,000 | BSE |
| JITEN KUMAR BISWAS | Bulk | Sell | 20 Nov 2025 | 3.74 | 140,000 | BSE |
| NILESH M SUHAGIYA | Bulk | Purchase | 17 Nov 2025 | 3.94 | 152,000 | BSE |
| NILESH M SUHAGIYA | Bulk | Purchase | 12 Nov 2025 | 3.92 | 296,000 | BSE |
| JITEN KUMAR BISWAS | Bulk | Sell | 12 Nov 2025 | 3.92 | 136,000 | BSE |
Evoq Remedies Corporate Actions
Evoq Remedies Board Meetings
Evoq Remedies past and upcoming board meetings.
#Ex-Date | Purpose | Notes |
|---|---|---|
130 May 2026 | Half Yearly Results | (Revised) |
210 Oct 2025 | Quarterly Results | - |
306 May 2025 | Preferential issue of shares | - |
429 Apr 2025 | Others | Inter-alia, to consider 1. Raising of funds upto Rs. 99.00 Crores by way of issue of Warrants. 2. Issuance of Equity shares other than cash through swap of shares. 3. Other business matters. (Revised) |
510 Apr 2025 | Audited Results | - |
Evoq Remedies Corporate Filings
Evoq Remedies BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.
| Date | Announcement Title | Details | Links |
|---|---|---|---|
| 15 Oct 2026 | Evoq Remedies Ltd - 543500 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 | Certificate under Regulation 74(5) of SEBI (DP) Regulation , 2018 | |
| 01 Oct 2026 | Evoq Remedies Ltd - 543500 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Approval Of Extension Of Time For Holding 16Th Annual General Meeting ('AGM') For The Financial Year Ended 31St March 2026 | Approval of Extension of time for holding 16th Annual General Meeting for the Financial Year ended 31st March, 2026 | |
| 30 Sep 2026 | Evoq Remedies Ltd - 543500 - Closure of Trading Window | Intimation of Closure of Trading Window | |
| 11 Jun 2026 | Evoq Remedies Ltd - 543500 - Corporate Insolvency Resolution Process (CIRP)-Admission of application by Tribunal | Corporate Insolvency Resolution Process (CIRP) - Admission of application by Tribunal | |
| 10 Jun 2026 | Evoq Remedies Ltd - 543500 - Corporate Insolvency Resolution Process (CIRP)-Admission of application by Tribunal | Corporate Insolvency Resolution process (CIRP) - Admission of application by Tribunal |
Evoq Remedies - Company Profile
Evoq Remedies Management Structure
Evoq Remedies management structure with salaries, total experience, and qualifications.
Evoq Remedies Board of Directors
Evoq Remedies Board of directors with salaries, total experience, and qualifications.
Website: www.evoqremedies.com
About the company - Business Profile
Evoq Remedies Ltd. is a pharmaceutical company primarily engaged in the trading of pharmaceutical products and raw materials. Based in Ahmedabad, the company operates within the SME segment and focuses on the distribution and supply of pharmaceutical formulations and chemicals. It serves as an intermediary in the healthcare supply chain, leveraging its network to provide various medicinal products to the market.
Key Points
- Key Facts:
- Founded Year: Incorporated in 2010.
- Headquarters: Ahmedabad, Gujarat, India.
- Stock Listing: Listed on the BSE SME exchange (Security ID: EVOQ, Code: 543500).
- Core Management: Bhumishth Narendrabhai Patel serves as the Managing Director.
- Operations and Resources:
- The company operates from its registered office at Empire Business Hub, Science City Road, Ahmedabad.
- As of September 30, 2025, the company reported tangible fixed assets (net) valued at ₹19.27 Lakhs.
- The company's primary operational focus is on the trading of pharmaceutical goods.
- Market and Significance:
- Evoq Remedies operates in a single reportable segment: Trading of Goods.
- Its business model is centered on the procurement and distribution of pharmaceutical formulations, which is critical for maintaining the supply of medicines to healthcare providers.
- Financial Overview (Annual and Half-Yearly):
- Revenue from Operations: For the fiscal year ended March 31, 2025, the company reported a total revenue of ₹1175.67 Lakhs. For the half-year ended September 30, 2025, revenue stood at ₹2,550.00 Lakhs, indicating significant sequential growth.
- Net Profit: The company reported a Profit After Tax (PAT) of ₹12.82 Lakhs for the full year ended March 31, 2025. For the half-year ended September 30, 2025, the PAT was ₹7.88 Lakhs.
- Expenditure: Major expenses for the half-year ended September 30, 2025, included the purchase of stock-in-trade (₹2,432.12 Lakhs) and employee benefit expenses (₹3.84 Lakhs).
- Assets and Liabilities:
- Share Capital: As of September 30, 2025, the share capital was ₹2,490.00 Lakhs, following changes from ₹7,490.00 Lakhs in March 2025.
- Total Assets: The total assets as of September 30, 2025, were ₹5,221.50 Lakhs, with current assets comprising the majority (₹5,201.83 Lakhs).
- Trade Receivables: Trade receivables significantly decreased from ₹861.67 Lakhs in March 2025 to ₹19.04 Lakhs in September 2025.
- Strategic Initiatives:
- The company continues to focus on its core trading operations while managing its working capital, evidenced by a significant reduction in trade receivables and an increase in short-term loans and advances (₹3,205.30 Lakhs as of September 2025).
References
